Prof Laura Lechuga is confident that in the near future, a portable device for early diagnosis of diseases such as malaria or cancer will be launched in the market.
You are here: Home
The nanoB2A Group
The nanoB2A Group focuses on the development of photonic and nanomechanical nanobiosensor devices of high sensitivity for label-free detection; biofunctionalization of surfaces; and the integration in lab-on-a-chip microsystems for real field diagnostics applications.
What We Do
We develop biosensors based on plasmonics, evanescent wave sensing and on nanomechanical changes, with high sensitivity and selectivity.
The Bioanalytical Applications research activities cover the detection of a wide range of molecules, of high interest in diverse fields as clinical diagnostic, environmental control, genomic and proteomic, under laboratory and real conditions and using the biosensor devices developed within the Group.
Early Detection of Diseases and Pathogens
Integration of multibiosensor arrays on Lab-on-a-chip platforms will allow the early detection of diseases and pathogens (in vitro and in-vivo).
Interview Prof. Laura Lechuga in “La Vanguardia.com”: “La ciencia en España está a punto de entrar en la UCI”
on March 12, 2014 in News